Researchers assess the differences in out-of-pocket spending on brand name compared with generic medication.
|Articles|January 25, 2008
Once-daily amoxicillin approved
Moxatag is the name of a new once-daily amoxicillin product for pharyngitis and tonsillitis following strep throat
Advertisement
MiddleBrook Pharmaceuticals' Moxatag (amoxicillin extended-release) Tablets 775 mg have been approved to treat adults and children 12 and older with pharyngitis and/or tonsillitis secondary to strep throat. The Germantown, Md., firm claims that its product is the first once-daily amoxicillin product approved in this country. Its convenient dosing should ensure better drug compliance.
To see more Daily News articles,
To go to the Drug Topics homepage,
Advertisement
Related to this article
Practical takeaways to improve real‑world clinic outcomes for PAINWeek 2026.
Starting with Exelixis’ condition on in-house dispensing data, manufacturers are introducing a new approach to 340B claims focused on transparency.
The trial found that up to 25 days of nirmatrelvir-ritonavir did not improve cognitive, autonomic, or exercise-related symptoms compared with placebo.
Digital innovation and proactive patient care are converging to transform clinical practice while preserving essential safeguards.
James Barnes, CPhT, explains why respecting a patient's time isn't about speed and how he landed in the pharmacy by chance.
ACIP changes, new court rulings, and coverage gaps threaten vaccines, pharmacists’ reimbursement, and children's access through Vaccine For Children.
As pouched products increase in popularity, researchers assess their pharmacology, harm-reduction potential, and initiation risk.
Advertisement
Advertisement
Trending on Drug Topics
1
Johnson & Johnson Next Major Drugmaker to Require 340B Claims Data
2
Nicotine Pouches Create Opportunity for Pharmacist Counseling
3
Nirmatrelvir-Ritonavir Shows No Benefit for Long COVID
4
Worth a Shot: How ACIP Changes Might Impact Vaccine Access, Coverage
5